Key statistics
As of last trade Esperion Therapeutics Inc (0IIM:LSE) traded at 2.46, -26.84% below its 52-week high of 3.37, set on Apr 05, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | 2.46 |
Low | 2.46 |
Bid | -- |
Offer | -- |
Previous close | 2.49 |
Average volume | 20.49k |
---|---|
Shares outstanding | 197.04m |
Free float | 196.05m |
P/E (TTM) | -- |
Market cap | 486.68m USD |
EPS (TTM) | -0.6585 USD |
Data delayed at least 20 minutes, as of Nov 22 2024 14:50 GMT.
More ▼
Announcements
- Esperion to Participate in Upcoming Piper Sandler 36th Annual Healthcare Conference
- Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024
- Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- Esperion Reports Third Quarter 2024 Financial Results and Provides a Business Update
- Esperion to Participate in Upcoming Jefferies London Healthcare Conference
- Esperion Announces a Featured Presentation in the Late Breaker/Featured Science Track and Three Poster Presentations Accepted for the 2024 American Heart Association (AHA) Scientific Sessions
- Esperion to Report Third Quarter 2024 Financial Results on November 7
- Esperion EU Partner Reports Final Real-World Results from MILOS German Cohort Demonstrating Strong Increase in LDL-C Goal Achievement With Addition of Bempedoic Acid
- Esperion Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
- Esperion to Participate in Upcoming 2024 Cantor Global Healthcare Conference
More ▼